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ORIGINAL RESEARCH
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ABSTRACT
In this study we evaluated the potential of expanded NK cells (eNKs) from two sources combined with the mAbs 
daratumumab and pembrolizumab to target primary multiple myeloma (MM) cells ex vivo. In order to ascertain 
the best source of NK cells, we expanded and activated NK cells from peripheral blood (PB) of healthy adult 
donors and from umbilical cord blood (UCB). The resulting expanded NK (eNK) cells express CD16, necessary for 
carrying out antibody-dependent cellular cytotoxicity (ADCC). Cytotoxicity assays were performed on bone 
marrow aspirates of 18 MM patients and 4 patients with monoclonal gammopathy of undetermined signifi-
cance (MGUS). Expression levels of PD-1 on eNKs and PD-L1 on MM and MGUS cells were also quantified. Results 
indicate that most eNKs obtained using our expansion protocol express a low percentage of PD-1+ cells. UCB 
eNKs were highly cytotoxic against MM cells and addition of daratumumab or pembrolizumab did not further 
increase their cytotoxicity. PB eNKs, while effective against MM cells, were significantly more cytotoxic when 
combined with daratumumab. In a minority of cases, eNK cells showed a detectable population of PD1+ cells. 
This correlated with low cytotoxic activity, particularly in UCB eNKs. Addition of pembrolizumab did not restore 
their activity. Results indicate that UCB eNKs are to be preferentially used against MM in the absence of 
daratumumab while PB eNKs have significant cytotoxic advantage when combined with this mAb.
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The immune system largely prevents the development of tumors 
but clinical cancers evade this immune surveillance. Multiple 
pathways help create an immunosuppressive tumor environ-
ment, interfering with tumor antigen presentation to cytotoxic 
T cells.1 Tumor cells hide the expression of tumor-specific anti-
gens, limiting the specific T cell anti-tumor response.2 NK cells, 
which are not antigen specific, provide a potent antitumor 
response and are a source of powerful immunotherapies.3 NK 
cells are used in the clinic, especially in hematological cancers 
with poor prognosis, and can safely be used in allogeneic 
settings.4–6 Their combination with anti-tumor antibodies, 
through antibody-dependent cellular cytotoxicity (ADCC), 
offers interesting therapeutic opportunities.7,8
The immune checkpoints refer to molecules that inhibit or 
modulate immune responses, being CTLA-4 and PD-1 the two 
most studied, especially in the context of T cell activation.9–11 
The use of anti-PD1 blocking antibodies such as pembrolizu-
mab and nivolumab has become a first-line treatment in 
tumors with poor prognosis.12,13 Some reports indicate that 
PD-L1 expression in tumor cells results in functional impair-
ment of PD-1+ NK cells.14–16 While certain reports show that 
NK cell function can be partially restored using blocking 
mAbs,15,16 others show a more acute impairment that requires 
cytokines such as IL-2 and IL-15 for functional restoration.14 
Regarding NK cells, additional molecules act as checkpoint 
inhibitors, such as the inhibitory NK cell receptor NKG2A, 
which inhibits NK cell activity when ligated by HLA-E, 
expressed on the surface of tumor cells. The use of a NKG2A 
blocking mAb, monalizumab, offers promise as a new tumor 
immunotherapy.17 Other NK cell checkpoint mechanisms 
include blocking the activating receptor NKG2D by tumor 
shedding of their MIC ligands,18 or the negative action of 
LAG-3 and TIM-3.19
Multiple myeloma (MM) arises from uncontrolled prolif-
eration of abnormal plasma cells and accounts for 10–20% of 
all hematological neoplasms and 0.9% of all newly diagnosed 
cancer cases worldwide.20 MM is normally preceded by 
a premalignant phase, termed monoclonal gammopathy of 
undetermined significance (MGUS). MGUS is found in 3% of 
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the population above the age of 50, but the rate of progression 
from MGUS to MM is very low.21 Over the past two decades, 
treatment regimens and survival rates of MM patients have 
witnessed a radical improvement, with proteasome inhibitors 
and monoclonal antibodies (mAbs) as the main contributors.22 
However, although overall survival and patient outcomes have 
considerably improved, drug resistance is still a major 
concern,23 mainly in high-risk patients, such as patients with 
t(4;14) or del17p. For this reason, novel and more efficient 
therapeutic approaches are needed.
NK cell-based immunotherapy could have a positive impact 
in MM treatment. One obstacle is the immunosuppressive 
tumor microenvironment present in MM patients, in whom 
almost all arms of the immune system are subverted.24 For 
example, NK cells from MM patients are ineffective against 
disease progression.25 Hence, allogeneic activated and expanded 
NK cells could be an interesting approach. In fact, NK-based 
treatments have been recently optimized for its use in MM,26–30 
including a combination of a tumor NK cell line with the anti- 
CD38 mAb daratumumab.31
CD38 is highly expressed in aberrant MM cells while its 
expression on normal lymphoid cells, including plasma cells, is 
relatively low. Daratumumab shows efficacy in relapsed and 
refractory MM patients treated with at least two prior lines of 
therapy.32–34 NK cell-mediated cytotoxicity seems to be one of 
the main mechanisms for its anti-MM activity. Since patient 
NK cell status is variable, this could explain difference in 
responses among patients.35
Certain reports indicate PD-L1 expression in MM cells which 
correlates with disease progression from the MGUS stage.36,37 
However, clinical trials using PD-1 or PD-L1 blockers, alone or 
in combination with other treatments have failed in MM.38
The potent cytotoxicity of activated NK cells from PB39–41 
or UCB cells7,42 against a variety of malignancies has pre-
viously been published by our laboratories. In one study, the 
expansion of these UCB NK cells was also reported.7 In the 
present work, we compare the cytotoxic capacity of PB and 
UCB eNKs against MM patient samples.
2. Results
2.1. Peripheral and umbilical cord blood NK expansion
NK cells were expanded using two different protocols. UCB 
NK cells, due to their need for both KIR and KAR signals to 
reach a mature phenotype, were cultured with PLH, an EBV- 
transformed HLA-I+ B lymphoblastoid cell line which works as 
an accessory cell with both required signals.7 Conversely, PB 
NKs are fully mature and need only activating signals thus the 
EBV+ HLA-I negative cell line 721.221 was employed.43 As 
a first step, T cells and NKT cells were depleted from the 
cultures using anti-CD3 mAb, to favor NK cell expansion 
(see Figure 1(a), d 0). Each protocol required different ratios 
of accessory cells, while IL-2 and IL-15 were added at the same 
concentrations. UCB NKs were treated with accessory cells and 
cytokines every 3 d and benefited from little manipulation. PB 
Figure 1. Progression of NK phenotypes through the expansion protocol. Flow cytometry dot plots showing CD3 APC (y-axis) and CD56 PE Vio 770 (x-axis) staining of PB 
(a) and UCB (b) NKs from d 0 through d 20 of expansion protocol indicated in materials and methods. Histograms depict the progression of PB (c) and UCB (d) NK cells 
expressing CD16 throughout the 20-d expansion. Numbers indicate the percentage of CD16+ NK cells. Cells were stained with CD16 VioBlue or PerCP, as indicated. Lines 
correlate to testing every 5 d.
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NKs were sustained for 5–6 d before culture renewal and 
withstood daily manipulation seen in Figure 1. By d 20, almost 
all cells from both sources present in the culture were 
CD56+CD3− NK cells (see Figure 1(a,b)). The purity of NK 
cells was 94.28 ± 2.08% for UCB and 95.8 ± 1.46% as an average 
(see Suppl. Figure 1 and Suppl. Table I). The CD3+ fraction, 
which was successfully depleted at d 0, did not overtake the 
CD56+ population, allowing for successful expansion of NK 
cells (Figure 1(a,b)). Beginning with 1E6 NKs in each expan-
sion, PB NKs reached an average of 240E6 cells by d 20 and 
UCB NKs averaged a 700-fold expansion (Suppl. Fig 2).
The initial characterization of the phenotype of NK cells 
expanded using EBV-transformed LCL as feeders has been 
performed in previous studies of our laboratories. A detailed 
description of all genes and miRNA expressed upon 
a 5-d activation is found in.44 The expression of specific acti-
vating and inhibitory NK cell receptors was studied following 
this 5-d activation protocol, showing increases in the percen-
tage of NKp30+ and especially NKp44+ populations.40 The 
phenotype of eNK cells following these expansion and activa-
tion protocols as compared to freshly isolated NK cells has also 
been studied in previous work from our groups. eNK cells from 
UCB show increased expression of activation markers such as 
CD69 and reduced that of CD45RA, becoming CD45RAdim 
cells, keeping high CD16 expression.7 Regarding eNK cells 
obtained from PB, the significant increase in the NKp44+ 
population previously described in Sanchez-Martinez et al.40 
was clearly confirmed in our latest study.45 Consequently, we 
have determined the expression of NKp44 ligands on the sur-
face of patient MM cells and found faint levels of expression 
(Suppl. Fig 3). Their scant expression level does not justify the 
increase in cytotoxicity of eNKs. Rather, this increase in cyto-
toxicity could more closely be related to the previously demon-
strated increase in granzyme B expression observed in 
activated NK cells.40
Regarding CD16 expression, PB NKs presented high levels 
at d 0, which was maintained throughout the expansion pro-
tocol (see a representative expansion in Figure 1(c) and 
a summary of data on all donors in Suppl. Table II). In general, 
fresh UCB NKs also showed CD16 expression, and this level of 
expression was also maintained during the expansions (see 
a representative expansion in Figure 1(d) and a summary of 
data on all donors in Suppl. Table II). The maintenance of 
CD16 expression in the expanded NK cells is important in 
order to combine them with therapeutic antibodies.
As the average purity of NK cells at d 20 averaged 95%, we 
did not proceed with further NK cell isolation before the 
cytotoxicity experiments. We estimated that both types of 
eNK cells could be used in cytotoxicity experiments from 
d 10 on, though expansion continued until d 20 to obtain 
a maximum number of eNK cells.
2.2. Limited fratricide of eNKs in the presence of 
daratumumab
As NK cells can express CD38, we have analyzed this point in 
our expanded NK cells. We show in Figure 2(a) the CD38 
expression in the 10 expansions performed. All expansions 
expressed CD38 to varying degrees. While most expansions 
had CD38 expression in the majority of their NK cell popula-
tion, a few expansions from both PB and UCB expressed CD38 
in only a minority of the eNK cell population. As daratumu-
mab binds to CD38, when CD38+ NKs are in the presence of 
daratumumab, cross-linking can occur between NK cells 
Figure 2. A. CD38 expression determined by flow cytometry on d-20 expanded NK cells (eNK), obtained from PB or from UCB; B, D-20 expanded NK cells (eNK) obtained 
from PB (left panel) or from UCB (right panel) were left untreated (Control), or they were incubated for 4 h with 5 μg/ml of daratumumab and/or 10 µg/ml of 
pembrolizumab, as indicated. After the incubations, eNK cell death was estimated by 7-ADD labeling. Horizontal lines indicate the mean cell death in each experimental 
condition.
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leading to cell killing via ADCC.46 The daratumumab-induced 
fratricide among NK cells could deplete the number of func-
tional eNK cells available to act against MM cells. To examine 
the extent of fratricide in our eNK cells, we cultured the eNKs 
from PB or UCB with daratumumab and/or pembrolizumab, 
as a secondary control. Daratumumab exhibited a limited cyto-
toxic effect, averaging less than 5% of specific cell death (Figure 
2(b)). Higher levels of CD38 expression on NK cells did not 
correlate with increased fratricide. Pembrolizumab did not 
have a cytotoxic effect alone or when combined with daratu-
mumab. We conclude that daratumumab-induced fratricide 
would not significantly impair eNK cytotoxic potential, 
although this should be tested in each eNK preparation before 
use.
2.3. PD-1 expression on eNK cells
Next, we tested PD-1 expression in the 5 PB and 5 UCB 
eNK used in our study. As shown in Figure 3, most eNK 
cells obtained (4 out of 5 both in the case of PB and UCB), 
showed a very limited population positive for PD-1 expres-
sion: between 3.9% and 8.3% of the total eNK population in 
the case of eNK derived from PB and between a 6.5% and 
a 12.7% in eNK cells derived from UCB. However, eNK 
cells from PB2 and UCB1 showed the presence of a defined 
and significant population positive for PD-1 expression, 
which accounted for 30.9% in PB2 and 23.13% in UCB1. 
The MFI of the whole eNK population in UCB1 was 4146 
while the average MFI in the other 4 UCBs was 1615. In 
the PB expansions, the MFI value for PB2 was 1481, while 
the average of the other 4 donors was 766. The population 
of eNK cells positive for PD-1 expression was never higher 
than 31%, remaining a minor subset of the whole eNK 
population. This result is in agreement with the reported 
low PD-1 expression in most eNK cells obtained from PB 
in our previous study.45
2.4. eNK cytotoxicity assays against MM and MGUS 
patient samples
We first obtained bone marrow aspirates of MM and MGUS 
from 22 patients at different stages of disease. Half of the MM 
patients had undergone at least one previous treatment and 
had experienced recurrence. Patient 1 (MM1) underwent six 
previous treatments and had again relapsed. MGUS patients 
were monitored but had received no treatment at the time of 
the bone marrow biopsies. Their clinical data are presented in 
Table 1. All samples were frozen in liquid nitrogen at the 
moment of extraction and thawed before being used in the 
cytotoxicity assays.
To analyze the therapeutic potential of both PB and UCB 
eNKs, we tested them against the same patient samples in the 
presence or in the absence of the mAbs. In order to better 
understand the effect of PD-1 expression on the cytotoxic 
ability of eNKs, results were stratified attending to PD-1 
expression in eNKs.
We first focused on results obtained using PD-1 negative 
eNK cells on MM patient samples (Figure 4). Neither daratu-
mumab nor pembrolizumab, alone or in combination, had 
a significant cytotoxic effect on MM samples (Figure 4(a)).
On average, UCB eNKs were more cytotoxic on MM cells 
than PB eNKs when used as lone treatment (Figure 4(a,b)). 
UCB eNKs cytotoxicity was not significantly increased with the 
addition of daratumumab. This was not due to low CD16 
expression, which was observed in more than 80% of the 
different UCB eNKs population (see Figure 1(d) and Suppl. 
Figure 3. A. Pattern of PD-1 expression on all d-20 expanded NK cells (eNK) used in the study, obtained from PB (upper panels) or from UCB (lower panels). B, Summary 
of the percentages of PD-1+ eNK cells obtained from UCB or from PB, as indicated.
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Table II). In contrast, PB eNKs increased their specific cyto-
toxicity when combined with daratumumab from 25% to 38% 
on average (Figure 4(b)), close to the level obtained by using 
UCB eNKs alone. Finally, as expected, pembrolizumab had no 
significant effect on these PD-1–negative eNKs (Figure 4(a,b)).
Neither daratumumab nor pembrolizumab exhibited appre-
ciable cytotoxicity when used alone or in combination on 
MGUS samples (Figure 5(a)). When eNKs were tested on 
MGUS cells, we observed again a significantly higher cytotoxi-
city of UCB eNKs than PB eNKs on the same samples (Figure 5 
(a,b)). Cytotoxicity of UCB eNKs was slightly higher on MGUS 
cells than on MM cells. Again, the combination with daratu-
mumab did not further increase the high level of UCB eNK 
cytotoxicity. Although we did not find any effect of pembroli-
zumab on MM cells, we observed a small average increase of 
cytotoxicity of PB eNKs on MGUS samples, but it was not 
statistically significant. The increase in cytotoxicity when com-
bining PB eNKs with daratumumab, although observed, was 
also not statistically significant. Pembrolizumab had no further 
effect. Cytotoxicity of PB eNKs was also higher on MGUS than 
on MM cells. These data, obtained with eNKs from both PB 
and UCB, could indicate that MGUS patients may benefit from 
eNK treatment prior to disease progression.
2.5. Cytotoxicity of eNK cells with a significant PD-1+ 
population
Figure 6(a,c) show results obtained with samples from the three 
patients treated with the only eNK obtained from PB that 
contained a significant PD-1+ population (PB2). Curiously, 
the eNK from PB2 showed a higher overall average cytotoxicity 
than that observed using PD-1-negative PB eNKs, around 40% 
of specific cell death (Figure 6(c)). However, the increase in 
cytotoxicity when PB eNKs were combined with daratumu-
mab, and previously observed in Figure 4, was lost.
For the four patient samples treated with the only eNK 
obtained from UCB that contained a significant PD-1+ popula-
tion (UCB1), we observed a dramatic decrease in cytotoxicity 
when compared to results obtained from PD-1-negative UCB 
eNKs (Figure 6(b,d)). The specific cell death average dropped 
from 42% (see Figure 4(b)) to 20%. This low cytotoxicity level 
was not due to resistance of the patient samples themselves, as 
cells from these same patients were sensitive to PD-1-negative 
PB1 eNKs, as shown in Figure 4. Addition of daratumumab did 
not increase the cytotoxicity of these eNKs, even though CD16 
Table 1. MM and MGUS patient clinical data. (A) Age and previous treatment data 
were calculated based on the date of patient bone marrow biopsy. For MGUS 
patients, no treatment was given. The Durie-Salmon score is not applicable (NA) 
to MGUS patients. PD-L1 expression is based on our data. Patients with 0 previous 
treatments indicate newly diagnosed MM. (B) Numbers of MM patients treated 
with each of the UCB or PB NK cell expansions. (C) Numbers of MGUS patients 
treated with each of the UCB or PB NK cell expansions.
A
MM 18 (82%) MGUS 4 (18%)
Age
(at time of sample)
Mean, years (range) 68 (45–83) 59 (49–77)
Gender
Male 12 (67%) 3 (75%)
Female 6 (33%) 1 (25%)
Durie Salmon score
I 5 (28%) NA
II 4 (22%) NA
III 9 (50%) NA
Previous treatments 
(at time of sample)
0 9 (50%) NA
1 4 (22%) NA
2 2 (11%) NA
3+ 3 (17%) NA
PD-L1 Expression
+ (>50% cells+) 9 (50%) 0 (0%)
– (<50% cells+) 9 (50%) 4 (100%)
B











Figure 4. eNK cytotoxicity assays on samples from MM patients. Cells from MM patients were left untreated (MM), or they treated with daratumumab at 5 μg/ml (d), 
with pembrolizumab at 10 μg/ml (p), or with their combination (D + P), or incubated with PD-1-negative UCB or PB eNKs for 4 h, as indicated, in the absence of in the 
presence of the indicated concentrations of daratumumab, pembrolizumab, or their combination. After the incubations, cell death was estimated by 7-AAD labeling in 
gated target cells (a), as indicated in Material and Methods. In (b) results are shown as the percentage of specific cell death induced, after subtracting basal cell death in 
each sample. Horizontal lines indicate the mean cell death in each experimental condition. One way ANOVA, ANOVA post hoc Tukey’s analysis were applied for multiple 
comparisons among various groups. * indicates p value less than 0.05 and considered to be significant.
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expression was high. This decrease in cytotoxicity was not due 
to the inhibitory effect of PD-1 because pembrolizumab did not 
increase cytotoxicity on any of the four patients tested. 
Interestingly, UCB1 was the only expansion that stopped pro-
liferating at d 15 (see Suppl. Fig 2).
To complete the information on the cytotoxicity experi-
ments, we include as Supplementary Figure 4 the individual 
cytotoxicity data obtained from the 22 patient samples, each 
treated with the eNK cells delineated in Table 1(b,c).
2.6. Pattern of PD-L1 expression in MM cells
In order to better understand the possible role of the PD-1/PD- 
L1 axis in the regulation of eNK cytotoxicity, we analyzed the 
PD-L1 levels of each MM sample (Figure 7(a)). In most of the 
samples, a population of PD-L1+ cells could be detected among 
MM cells, 40% being the average value. Only MM3 could be 
considered negative for PD-L1 expression. Thus, we divided 
MM samples as PD-L1high or PD-L1low depending on whether 
Figure 5. eNK cytotoxicity assays on samples from MGUS patients. Cells from MGUS patients were left untreated (MGUS), or they were treated with daratumumab at 
5 μg/ml (d), with pembrolizumab at 10 μg/ml (p), or with their combination (D + P), or incubated with PD-1-negative UCB or PB eNKs for 4 h, as indicated, in the absence 
of in the presence of the indicated concentrations of daratumumab, pembrolizumab, or their combination. After the incubations, cell death was estimated by 7-AAD 
labeling in gated target cells (a), as indicated in Material and Methods. In (b) results are shown as the percentage of specific cell death induced, after subtracting basal 
cell death in each sample. Horizontal lines indicate the mean cell death in each experimental condition. One way ANOVA, ANOVA post hoc Tukey’s analysis were applied 
for multiple comparisons among various groups. * indicates p value less than 0.05 and considered to be significant.
Figure 6. Cytotoxicity of eNK cells that contained a PD-1+ population. (a, c) Cells from the three indicated MM patients were left untreated (MM), or they were treated 
with daratumumab at 5 μg/ml (d), with pembrolizumab at 10 μg/ml (p), or with their combination (D + P), or incubated with eNK cells from PB2 for 4 h, as indicated, in 
the absence of in the presence of the indicated concentrations of daratumumab, pembrolizumab, or their combination. (b, d) Cells from the four indicated MM patients 
were left untreated (MM), or they were treated with daratumumab at 5 μg/ml (D), with pembrolizumab at 10 μg/ml (P), or with their combination (D + P), or incubated 
with eNK cells from UCB1 for 4 h, as indicated, in the absence of in the presence of the indicated concentrations of daratumumab, pembrolizumab, or their combination 
After the incubations, cell death was estimated by 7-AAD labeling in gated target cells (a, b), as indicated in Material and Methods. In (c, d) results are shown as the 
percentage of specific cell death induced, after subtracting basal cell death in each sample. Horizontal lines indicate the mean cell death in each experimental condition.
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this population accounted for more or less than 40%, respec-
tively. Nine patients fell into each category, although within 
each group there was high variability in expression levels. The 
average MFI value in the patients considered PD-L1high was 
10819, while in the patients considered PD-L1low was 5720. 
The PD-L1 labeling for each individual MM and MGUS 
patient is shown in Suppl. Fig 5. We confirm previous data 
indicating that MGUS cells are negative for PD-L1 expression, 
while most MM samples showed PD-L1 expression to some 
degree.35
Taking into account that only few NK cell expansions con-
tained a significant PD-1+ population (PB2 and UCB1), we 
were able to study the effect of pairing these eNK cells with PD- 
L1high MM cells only in one patient for each UCB and PB 
eNKs. Patient 9 (MM9), in which 79% of the cells expressed 
PD-L1, was one of the patients treated with the PB2 eNKs. The 
cytotoxicity of PB2 eNKs on MM9 cells was intermediate 
(Figure 7(b), red bars). Of the MM samples treated with these 
eNKs, MM9 exhibited one of the lowest levels of cytotoxicity 
(see Figure 6(a,b)). In this respect, the interaction of PD-1 on 
eNKs with PD-L1 on MM cells correlates with rather low 
cytotoxicity levels. A slight increase in cytotoxicity was 
observed when PB2 eNKs were combined with daratumumab. 
However, the expected increase in cytotoxicity due to PD-1 
blocking by pembrolizumab was not observed. MM9 cells were 
also treated with eNKs from the PD-1 negative UCB2. 
A similar level of cytotoxicity was observed, slightly increased 
by the combination with daratumumab and unaffected by 
incubation with pembrolizumab (Figure 7(b), blue bars).
Patient 1 (MM1) showed 54% of cells expressing PD-L1, 
and was one of the patients treated with the UCB1 eNKs. In 
agreement with results obtained from the other patients treated 
with this UCB, cytotoxicity was markedly low with no more 
than 10% of specific cell death induction (compare Figure 7(c), 
red bars, with Figure 6(c,d)). Neither daratumumab nor PD-1 
blocking with pembrolizumab increased the cytotoxicity of 
UCB1 eNKs on cells from this patient. Of note, the same result 
was observed using the same UCB eNKs against MM cells from 
patients 2, 3 and 4 (Figure 6(c,d)) that were PD-L1low or 
negative (see Figure 7(a)). MM1 cells did not exhibit an intrin-
sic resistance to NK cell cytotoxicity, since when treated with 
eNKs from PB1, that were PD-1 negative, showed an inter-
mediate level of cytotoxicity, somewhat increased by combina-
tion with daratumumab (Figure 7(c), blue bars).
Pembrolizumab was active in the experimental conditions 
used in this study. When used in combination with two PB 
eNKs that exhibited PD-1 expression in a significant percen-
tage of cells, pembrolizumab was able to increase cytotoxicity 
on the PD-L1+ B-CLL cell line Mec-1 (Supplemental Fig. 6). 
When this assay was performed using another 5 PB eNKs that 
did not exhibit PD-1 expression, pembrolizumab was without 
effect (data not shown).
3. Discussion
The present work demonstrates how the activation and expan-
sion of allogeneic NK cells generates eNK cells that are active 
against MM cells. The activation and expansion were achieved 
in UCB and PB Nks by using LCL lymphoblasts as feeders in 
combination with IL-2 and IL-15. In both cases, the final eNK 
product exhibited CD16 expression on an important fraction 
of their population (more than 80%), which would allow for 
Figure 7. (a) Expression of PDL-1 on the surface of MM samples. The black line corresponds to the average value and is used to divide samples as PD-L1high and PD-L1low. 
Only cells from MM3 can be considered negative for PD-L1 expression. (b, c) Cytotoxicity assays using eNK cells that contained a PD-1+ population on PD-L1high MM 
samples. B, MM9, which is PD-L1high, was treated with PB2 eNK cells (red bars) or with PD-1 negative UCB2 eNK (blue bars). C, MM1, which is PD-L1high, was treated with 
UCB1 eNKs (red bars) or with PD-1 negative PB1 (blue bars). Cell death was tested by 7-AAD labeling, as indicated in the legends of Figures 4, 5 and 6. Results are shown 
as the percentage of specific cell death induced, after subtracting basal cell death, which was never higher than 15%.
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their combination with a variety of therapeutic mAbs directed 
against tumor antigens.7 This increase in cytotoxicity could be 
associated with increased expression of activation markers,7 
and of the activating receptor NKp44.45 Moreover, in 
a similar study using a 5-d activation protocol, it was shown 
that the main change justifying the increase in cytotoxicity was 
the net increase in the level of granzyme B expression in 
activated NK cells.40
We observed how UCB eNKs showed a higher average cyto-
toxicity on MM cells than PB eNKs. The combination of PB 
eNKs with the anti-CD38 mAb daratumumab, which is already 
an effective treatment in a fraction of MM patients, increased 
their cytotoxicity to the levels observed for UCB eNKs.
This is especially relevant as allogeneic NK cell activation- 
based therapy, alone or in combination with antibodies, is yet to 
be approved for treatment of MM. While CAR T cell technology is 
at the forefront of current studies, it is expensive and has detri-
mental side effects, such as humoral immunity inhibition that 
needs to be treated over long periods of time. eNK cell treatments 
do not generate a durable memory response and would not have 
this side effect. Given the wide variety of previous treatments 
undergone by the patients in this study, relapsed and refractory 
patients would benefit from and respond to eNK cell therapy.
MM patients present an immunosuppressive tumor micro-
environment, in which almost all arms of the immune system 
are subverted.22–24 Specifically, NK cell activity in MM patients 
is compromised and patient NK cells are ineffective against the 
development of the disease.25 However, clinical data indicate 
that NK cells could be a therapeutic strategy in MM. In 
a pioneering work, Shi used haplo-identical mismatched NK 
cells treated with IL-2 for 2 d (no expansion) resulting in 
positive outcomes in 5 out of 10 relapsed MM patients.29 
Another study used expanded NK cells from patients as 
a therapy, with response in 2 out of 7 patients.30 A similar 
study used expanded patient NK cells in combination with 
anti-myeloma drugs in five relapsed MM patients, showing 
partial but durable responses.26 Nevertheless, no studies have 
been performed using allogeneic expanded NK cells obtained 
from healthy donors. More recently, an increase in cytotoxicity 
has been demonstrated on ex-vivo cells obtained from MM 
patients by combining expanded NK cells with carfilzomib27 
and also by combining daratumumab with the transformed NK 
cell line KHYG1 transiently expressing CD16.31 Additionally, 
preclinical studies have demonstrated the efficiency of anti-CS1 
(SLAMF7, CD319) NK-CAR cells on MM cell lines.47 A recent 
study using a humanized mice model demonstrated a positive 
effect of combining NK cells with the anti-CD137 mAb urelu-
mab, but not with daratumumab.48
PD-1 is an inhibitory receptor present on NK cells and 
activated CD4+ and CD8+ T lymphocytes. It is involved in 
immunosuppression by binding to its ligands PD-L1 and PD- 
L2, the former showing a broader expression.9 MM is character-
ized by augmented PD-L1 expression49,50 and some reports 
indicate that PD-L1 expression correlates with disease progres-
sion from the MGUS stage.36,37 Because of that, several phase III 
clinical trials were conducted with checkpoint inhibitors in 
combination with established MM treatments:51 pembrolizumab 
plus lenalidomide and dexamethasone (Dex) (KEYNOTE-185, 
NTC02579863); pembrolizumab plus pomalidomide (Poma) 
and dexamethasone (KEYNOTE-183, NTC02576977); and 
another study testing three different combination regimens 
(Poma and Dex vs. nivolumab, Poma and Dex vs. nivolumab, 
elotuzumab, Poma and Dex; CheckMate 602, NCT02726581). 
However, these studies were discontinued due to an increase in 
deaths in the pembrolizumab group as well as no objective 
responses. Indeed, the FDA has put on hold another clinical 
trial combining the anti-PD-L1 mAb atezolizumab with daratu-
mumab for similar reasons (NCT02431208, see38).
Our data indicate that most eNK cells obtained using the 
protocol described showed a small population of PD-1+ cells, 
suggesting that this inhibitory pathway would have a low rele-
vance in the treatment of MM patients by these eNKs. However, 
in a minority of the cases, eNK cells showed a significant popula-
tion of PD1+ cells. Particularly in the case of UCB eNKs that 
contained this PD-1+ population, cell death induction on MM 
cells decreased dramatically and addition of pembrolizumab did 
not restore cytotoxicity. This result was observed on MM cells 
positive or negative for PD-L1 expression. This suggests that these 
eNK cells from UCB are intrinsically nonfunctional, independent 
of the PD-1 signaling pathway. This result indicates that the status 
of PD-1 expression in the final cellular UCB eNK product should 
be determined as a marker of lower cytotoxic activity.
The present data could be supported by studies in 3D 
cultures or in in vivo MM models. However, 3D cultures 
require relatively long-term periods in vitro. During this time, 
tumor cells express ligands that were not expressed ex vivo and 
down-modulate the expression of other molecules. Moreover, 
there is a selection bias of certain clones that grow better in 
in vitro culture. In contrast, we examined tumor cell sensitivity 
to eNK cells directly ex vivo, without culturing them in vitro. 
We chose to test tumor cell sensitivity to eNK cells quickly after 
obtaining the cells from the patient, avoiding culturing the 
tumor cells, a process that can affect their sensitivity to allo-
geneic NK cells. Likewise, similar problems can be envisaged in 
human MM cell engraftment in NSG mice, as the human 
microenvironment is not reproduced.
UCB, rather than PB, contains different NK cell progenitor 
populations with the capacity to differentiate into NK cells52 
and this could originate NK cells with higher cytolytic activity 
against primary MM cells. Interestingly, UCB NK cells, com-
pared to PB NK, have a higher expression of the bone marrow 
homing receptor CXCR452 and somehow this could help to 
recognize primary MM cells that niche in the bone marrow.
The present data indicate that UCB eNKs are to be prefer-
entially used against MM in the absence of daratumumab while 
PB eNKs have significant cytotoxic advantage when combined 
with this mAb. Our present data, obtained with MM patients 
ranging from newly diagnosed to relapsed/refractory, reinforce 
the feasibility of using allogeneic eNK cells in the treatment of 
MM, mainly in view of their high cytotoxicity against tumor 
cells in combination with daratumumab.
4. Materials and Methods
4.1. Ethical statement
The use of human specimens for scientific purposes was 
approved by the French National Ethics Committee. All 
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methods were carried out in accordance with the approved 
guidelines and regulations of this committee. Written informed 
consent was obtained from each patient or donor prior to 
surgery.
4.2. Bone marrow aspirates from multiple myeloma 
patients
Data and samples from patients were collected at the Clinical 
Hematology Department of the CHU Montpellier, France, 
after patient’s written consent and following French regula-
tions. Patients were enrolled in the HEMODIAG_2020 (ID- 
RCB: 2011-A00924-37) clinical program approved by the 
“Comités de Protection des Personnes Sud Méditerranée I” 
with the reference 1324. Samples were collected at diagnosis 
and kept by the CHU Montpellier. MM and MGUS samples 
were processed to isolate the mononuclear cell fraction from 
the bone marrow aspirate by density gradient centrifugation. 
Cells were then washed and frozen in a 10% DMSO solution in 
liquid nitrogen until use.
4.3. Feeder cell lines
721.221 and PLH are EBV+ transformed, human B-cell lym-
phoblastoid cell lines. Both were cultured in RPMI (Invitrogen) 
with 10% FBS at 37 C. Before use in the expansion protocol, 
cells were inactivated with γ-irradiation. PCR was carried out 
on cell lines periodically to test for mycoplasm contamination.
4.4. NK cell isolation and expansion
Peripheral blood was obtained from five individual donors of 
the “Etablissement Français du Sang (EFS)”. This work also 
benefited from umbilical cord blood units (UCBs) and the 
expertise of Prof. John De Vos, in charge of the Biological 
Resource Center Collection of the University Hospital of 
Montpellier – http://www.chu-montpellier.fr/en/platforms 
(BIOBANQUES Identifier – BB-0033-00031).
PBMCs and UCBMCs were isolated through density gradi-
ent centrifugation using Histopaque-1077 (Sigma). Blood sam-
ples were diluted at 1:1 ratio with RPMI then layered above 
10 mL Histopaque in a 50 mL conical tube. Once centrifuged 
for 30 minutes at 400xg, the white layers of mononuclear cells 
(MCs) were collected and washed.
Using EasySepTM Human CD3 Positive Isolation kit 
(StemCell Technologies), the CD3+ cell fraction (T and 
NKT cells) of the MCs was depleted in each sample to 
better culture the NK cells. Once depletion was verified 
through flow cytometry, cells were cultured for 20 d. UCB 
NKs were cultured with ϒ-irradiated PLH at a 1:4 (NK cell: 
feeder cell) ratio. PB NKs were cultured with ϒ -irradiated 
721.221 cells at a 5:1 (NK cell: feeder cell) ratio. The same 
concentration of IL-2 (100IU/mL) and IL-15 (5 ng/mL) 
were added to both NKs. Feeder cells and cytokines were 
refreshed every 3–4 d for UCB NKs and every 5 d for PB 
NKs. To monitor expansions, NK cells were stained with 
APC-labeled anti-CD3 mAb and PE or Vio770-labeled anti 
CD56 mAb (both from BD Biosciences) and the percentage 
of CD3−CD56+ cells estimated at each time point. At d 20, 
NK cell purity was 95% as average (see Suppl. Table I). 
Culture viability was determined at regular intervals 
through flow cytometry analysis.
4.5. FACS analysis
The expression of CD16 during the expansions was also esti-
mated by flow cytometry using VioBlue or PerCP. 
Cy5.5-labeled anti-CD16 mAb (BD Biosciences). The expres-
sion of PD-1 in the final eNK product was analyzed with PE- 
labeled anti-PD-1 mAb (BD Biosciences). PD-L1 expression in 
gated MM cells from patients (positive for CD38) was tested 
with an APC-labeled anti-PD-L1 mAb (BD Biosciences). Flow 
cytometry analysis was performed with Beckman Coulter 
Gallios and data analyzed using BC Kaluza Analysis Software.
4.6. Cytotoxicity assays of patient samples with eNKs and 
mAbs
The cytotoxic potential of eNKs and mAbs against target cells 
was determined through a flow cytometry cytotoxicity assay. 
Patient samples were removed from liquid nitrogen storage, 
washed and incubated at 37ºC for 30 minutes with relevant 
antibodies (daratumumab at 5 µg/ml, and pembrolizumab at 
10 µg/ml) prior to use in the assays. eNK cells were co-cultured 
with target cells at a 5:1 effector:target ratio in the presence or 
absence of the indicated mAbs and incubated for 4 hours at 
37ºC. Subsequently, cells were marked with an APC-labeled 
anti-CD38 mAb or with a PE-labeled anti-CD138 mAb (all 
from Beckman) and with 7-AAD. NK cells were excluded from 
the gating by their smaller size and lower CD38 expression 
than MM cells, or by the absence of CD138 expression, respec-
tively. MM cells present in the sample were gated using the 
CD38 or CD138 labeling and cell death estimated in the gated 
population by 7AAD positivity. In the samples where daratu-
mumab is used, there is a competition between the therapeutic 
mAb and the anti-CD38 mAb used for flow cytometry, so only 
a CD138-based gating was used. Basal cell death was calculated 
from control samples and values were subtracted from those 
obtained for treated cells to obtain specific cell death. It is 
possible that this flow cytometry method would underestimate 
cytotoxicity, since cell debris coming from dead cells cannot be 
included in the analysis.
4.7. Statistical analysis
Statistical data were obtained using GraphPad Prism (5.0). 
The statistical relevance of each study was first evaluated 
via ANOVA, analysis variance. For statistical significance 
(p < .05), Post-hoc Tukey’s analysis was employed.
5. Conclusions
NK cells are a promising source for cancer immunotherapy 
against hematological malignancies. Both UCB and PB are 
potential sources of NK cells. Our data present the optimal 
conditions for each eNK to produce maximal cytotoxicity 
against all types of MM – new, relapsed/refractory and MGUS. 
UCB eNKs were highly cytotoxic when used as monotherapy, 
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while PB eNKs combined with daratumumab had the greatest 
cytotoxic effect. These results indicate a potent future for eNK 
cell adoptive immunotherapy against MM and a need to tailor 
each eNK cell treatment based on treatment regimen.
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